• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Leahy Emer

    5/6/25 4:09:05 PM ET
    $INTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $INTS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Leahy Emer

    (Last) (First) (Middle)
    C/O INTENSITY THERAPEUTICS, INC.
    1 ENTERPRISE DRIVE, SUITE 430

    (Street)
    SHELTON CT 06484

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    INTENSITY THERAPEUTICS, INC. [ INTS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/02/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy Common Stock) $0.57 05/02/2025 A 50,000 (1) 05/02/2035 Common Stock 50,000 $0 50,000 D
    Explanation of Responses:
    1. This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on May 2, 2025.
    Remarks:
    Exhibit List - Exhibit 24 - Power of Attorney
    /s/ Joseph Talamo, Attorney-in-fact 05/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $INTS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INTS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $INTS
    Financials

    Live finance-specific insights

    See more
    • Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update

      32 sites are currently contracted in the INVINCIBLE-3 Study, and 25 patients have been screenedEight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been screenedFinal sarcoma data from our first metastatic study and our INVINCIBLE-3 Study design was presented at the annual Connective Tissue Oncology Society Meeting in November 2024Final data from our first neoadjuvant breast cancer study and our INVINCIBLE-4 Study design was presented at the annual San Antonio Breast Cancer Society Meeting in December 2024SHELTON, Conn., March 13, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology

      3/13/25 4:07:00 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

      First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer SHELTON, Conn., Nov. 13, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces third quarter 2024 financial results and provides a corporate update. Corporate Update INVINCIBLE-3 Study: a Phase 3 open-label, rand

      11/13/24 4:06:00 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INTS
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Intensity Therapeutics Inc.

      DEFA14A - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      6/2/25 4:02:41 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Intensity Therapeutics Inc.

      DEF 14A - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      6/2/25 4:01:48 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

      5/20/25 4:05:38 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $INTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $INTS
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form SC 13G filed by Intensity Therapeutics Inc.

      SC 13G - INTENSITY THERAPEUTICS, INC. (0001567264) (Subject)

      6/7/24 5:29:04 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Intensity Therapeutics Inc.

      SC 13G - INTENSITY THERAPEUTICS, INC. (0001567264) (Subject)

      2/13/24 4:01:30 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Principal Accounting Officer Wesolowski John M

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:21:05 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Dubin Thomas I H

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:11:54 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Donovan Daniel

      4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

      5/6/25 4:11:09 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

      SHELTON, Conn., May 15, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces the appointment of Thomas Dubin, J.D., MPH, to the Intensity Board of Directors, effective May 14, 2024. Mr. Dubin will serve as a member of the Audit Committee of the Board. In connection with Mr. Dubin's appointment, the size of the Board was increased from four directors to five. Of these five directors, four are independent pursuant to Nas

      5/15/24 8:01:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

      Mr. Talamo brings over 25 years of experience leading financial strategies to support both publicly traded and privately held development and commercial stage biopharmaceutical companies SHELTON, Conn., Dec. 12, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the appointment of Joseph Talamo as Chief Financial Officer (CFO). Mr. Talamo will be working at Intensity headquarters as a full time employee. An accomplished executive with more than

      12/12/23 8:01:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $INTS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

      SHELTON, Conn., May 29, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that the Company will be presenting a Trials in Progress poster outlining its Phase 3 INVINCIBLE-3 clinical trial of INT230-6 for the treatment of metastatic soft tissue sarcomas. The poster will be shown at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting held at McCormick Place in Chicago May 30-June 5, 2025.

      5/29/25 8:00:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

      SHELTON, Conn., May 28, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral investigational cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces a collaboration to educate patients with early stage breast cancer about potential new therapeutic options with model, author, executive producer, speaker, and breast cancer survivor Christine Handy. The film, Hello Beautiful, an adaptation of Ms. Handy's award-winning novel Walk Beside Me, recently won the Golden Palm Award at

      5/28/25 8:00:00 AM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been treatedEuropean Medicines Agency Authorization to initiate INVINCIBLE-4-Study in FranceSHELTON, Conn., May 13, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces first quarter 2025 financial results and provides a corporate update.

      5/13/25 4:06:00 PM ET
      $INTS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care